Collaboration Agreements (Tables)

6 Months Ended

Jun. 30, 2016

Summary of Revenue Recognized under Agreement

		Three Months Ended June 30,				Six Months Ended June 30,
Agreement	Deliverable	2016		2015		2016		2015
Japan	License	$	43	$	91	$	118	$	528
	Milestones		10,000		—		10,000		—
	Total license and milestone revenue		10,043	$	91	$	10,118	$	528
	Collaboration services revenue*		3	$	42	$	7	$	100

When and if available compounds, manufacturing — clinical supplies and committee services have each been identified as separate units of accounting with standalone value and amounts allocable to these elements have been recognized and classified within the Collaboration services revenue line item within the condensed consolidated statements of operations.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through June 30, 2016		Deferred Revenue at June 30, 2016		Total Consideration Through June 30, 2016
License	$	42,362	$	—	$	42,362
When and if available compounds		15		27		42
Manufacturing--clinical supplies		1,971		—		1,971
Committee services		17		—		17
Total license and collaboration services revenue	$	44,365	$	27	$	44,392

Europe [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Europe Agreement were as follows (in thousands):

		Three Months Ended June 30,				Six Months Ended June 30,
Agreement	Deliverable	2016		2015		2016		2015
Europe	License	$	3,000	$	4,769	$	6,238	$	9,024
	Milestones		—		—		—		—
	Total license and milestone revenue		3,000		4,769		6,238		9,024
	Collaboration services revenue*	$	323	$	677	$	671	$	1,253

When and if available compounds, manufacturing — clinical supplies, development services — in progress at the time of signing of the agreement, and committee services have each been identified as a separate unit of accounting with standalone value and amounts allocable to these units have been recognized in revenue as services are performed and classified within the Collaboration services revenue line item within the condensed consolidated statements of operations.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the Europe Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through June 30, 2016		Deferred Revenue at June 30, 2016		Total Consideration Through June 30, 2016
License	$	407,554	$	—	$	407,554
When and if available compounds		354		422		776
Manufacturing--clinical supplies		9,762		—		9,762
Development services--in progress		32,654		—		32,654
Committee services		278		4		282
Total license and collaboration services revenue	$	450,602	$	426	$	451,028

U.S./RoW [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the U.S./RoW Agreement were as follows (in thousands):

		Three Months Ended June 30,				Six Months Ended June 30,
Agreement	Deliverable	2016		2015		2016		2015
U.S. / RoW and China	License	$	60,154	$	87,019	$	76,579	$	93,833
	Milestones		—		15,000		—		15,000
	Total license and milestone revenue		60,154		102,019		76,579		108,833
	Collaboration services revenue*		15,755		12,942		23,939		17,080
	China single unit of accounting**	$	—	$	—	$	—	$	—

Co-development, information sharing, and committee services have been combined into a single unit of accounting because the requirements to share information and serve on committees are useful only in combination with the development services, and because all three items are delivered over the same period while manufacturing — clinical supplies has been identified as a separate unit of accounting with standalone value and amounts allocable to this unit of accounting have been recognized and classified within the Collaboration services revenue line item within the condensed consolidated statements of operations.

All revenues attributable to the China unit of accounting are deferred until all deliverables are met. The China license and collaboration services elements have been combined into a single unit of accounting and consideration allocable to this unit is being deferred due to FibroGen’s retention of manufacturing rights and lack of standalone value.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the U.S./RoW Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through June 30, 2016		Deferred Revenue at June 30, 2016		Total Consideration Through June 30, 2016
License	$	366,345	$	—	$	366,345
Co-development, information sharing & committee services		74,006		37,375		111,381
Manufacturing--clinical supplies		327		54		381
China-single unit of accounting		—		75,091		75,091
Total license and collaboration services revenue	$	440,678	$	112,520	$	553,198